210 related articles for article (PubMed ID: 35388215)
21. In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficile.
Marchandin H; Anjou C; Poulen G; Freeman J; Wilcox M; Jean-Pierre H; Barbut F
J Antimicrob Chemother; 2023 Aug; 78(8):1992-1999. PubMed ID: 37352110
[TBL] [Abstract][Full Text] [Related]
22. [Clostridioides difficile - New Insights and Therapy Recommendations].
Schönherr S; Jung L; Lübbert C
Dtsch Med Wochenschr; 2023 Jun; 148(12):752-758. PubMed ID: 37257477
[TBL] [Abstract][Full Text] [Related]
23. Characterization of the impact of rpoB mutations on the in vitro and in vivo competitive fitness of Clostridium difficile and susceptibility to fidaxomicin.
Kuehne SA; Dempster AW; Collery MM; Joshi N; Jowett J; Kelly ML; Cave R; Longshaw CM; Minton NP
J Antimicrob Chemother; 2018 Apr; 73(4):973-980. PubMed ID: 29253242
[TBL] [Abstract][Full Text] [Related]
24. Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3).
Lin W; Das K; Degen D; Mazumder A; Duchi D; Wang D; Ebright YW; Ebright RY; Sineva E; Gigliotti M; Srivastava A; Mandal S; Jiang Y; Liu Y; Yin R; Zhang Z; Eng ET; Thomas D; Donadio S; Zhang H; Zhang C; Kapanidis AN; Ebright RH
Mol Cell; 2018 Apr; 70(1):60-71.e15. PubMed ID: 29606590
[TBL] [Abstract][Full Text] [Related]
25. [Updated Czech guidelines for the treatment of patients with colitis due to Clostridioides difficile].
Beneš J; Stebel R; Musil V; Krůtová M; Vejmelka J; Kohout P
Klin Mikrobiol Infekc Lek; 2022 Sep; 28(3):77-94. PubMed ID: 36791303
[TBL] [Abstract][Full Text] [Related]
26. Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores.
Bassères E; Endres BT; Montes-Bravo N; Pérez-Soto N; Rashid T; Lancaster C; Begum K; Alam MJ; Paredes-Sabja D; Garey KW
Anaerobe; 2021 Jun; 69():102352. PubMed ID: 33640461
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoB.
Schwanbeck J; Riedel T; Laukien F; Schober I; Oehmig I; Zimmermann O; Overmann J; Groß U; Zautner AE; Bohne W
J Antimicrob Chemother; 2019 Jan; 74(1):6-10. PubMed ID: 30247587
[TBL] [Abstract][Full Text] [Related]
28. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
[No Abstract] [Full Text] [Related]
29. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.
Tashiro S; Mihara T; Sasaki M; Shimamura C; Shimamura R; Suzuki S; Yoshikawa M; Hasegawa T; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
J Infect Chemother; 2022 Nov; 28(11):1536-1545. PubMed ID: 35964806
[TBL] [Abstract][Full Text] [Related]
30. Phenolic Substitution in Fidaxomicin: A Semisynthetic Approach to Antibiotic Activity Across Species.
Jung E; Kraimps A; Dittmann S; Griesser T; Costafrolaz J; Mattenberger Y; Jurt S; Viollier PH; Sander P; Sievers S; Gademann K
Chembiochem; 2023 Dec; 24(24):e202300570. PubMed ID: 37728121
[TBL] [Abstract][Full Text] [Related]
31. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
[TBL] [Abstract][Full Text] [Related]
32. Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile.
Babakhani F; Seddon J; Sears P
Antimicrob Agents Chemother; 2014 May; 58(5):2934-7. PubMed ID: 24550338
[TBL] [Abstract][Full Text] [Related]
33.
Dureja C; Rutherford JT; Pavel FB; Norseeda K; Prah I; Sun D; Hevener KE; Hurdle JG
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0122223. PubMed ID: 38265216
[No Abstract] [Full Text] [Related]
34. Microbiome-preserving antibiotics for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis.
Kravets AM; Hanneke R; Nelson RL
Tech Coloproctol; 2023 Dec; 28(1):20. PubMed ID: 38112980
[TBL] [Abstract][Full Text] [Related]
35. Real-life experience with fidaxomicin in Clostridioides difficile infection: a multicentre cohort study on 244 episodes.
Escudero-Sánchez R; Valencia-Alijo A; Cuéllar Tovar S; Merino-de Lucas E; García Fernández S; Gutiérrez-Rojas Á; Ramos-Martínez A; Salavert Lletí M; Castro Hernández I; Giner L; Cobo J
Infection; 2021 Jun; 49(3):475-482. PubMed ID: 33417171
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of fidaxomicin use in community hospitals after a clinical guideline change at a large health system and opportunities for stewardship.
Khadem TM; Nguyen MH; Bariola JR
Infect Control Hosp Epidemiol; 2023 Feb; 44(2):312-314. PubMed ID: 35067241
[TBL] [Abstract][Full Text] [Related]
37. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
Okumura H; Ueyama M; Shoji S; English M
J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
[TBL] [Abstract][Full Text] [Related]
39. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection.
Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL
Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209
[TBL] [Abstract][Full Text] [Related]
40. A prospective, observational study of fidaxomicin use for
Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
